共 37 条
[1]
Boehncke WH(2015)Psoriasis Lancet 386 983-994
[2]
Schon MP(2020)Psoriasis and cardiovascular risk: a comprehensive review Adv Ther 37 2017-2033
[3]
Masson W(2021)Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification Drugs Today (Barc) 57 347-357
[4]
Lobo M(2018)Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials Lancet 392 650-661
[5]
Molinero G(2021)Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study Acta Derm Venereol 101 adv00605-969
[6]
Magina S(2015)Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) JAMA Dermatol 151 961-284
[7]
Filipe P(2011)Hepatitis B therapy Nat Rev Gasteroenterol Hepatol 8 275-5
[8]
Gordon KB(2021)Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single-center real-life population J Dermatolog Treat 15 1-398
[9]
Strober B(2017)EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection J Hepatol 67 370-123
[10]
Lebwohl M(2014)Anti-TNF therapy in patients with HBV infection—analysis of 87 patients with inflammatory arthritis Clin Rheumatol 33 119-482